Literature DB >> 24152424

Evidence for factor IX-independent roles for factor XIa in blood coagulation.

A Matafonov1, Q Cheng, Y Geng, I M Verhamme, O Umunakwe, E I Tucker, M-F Sun, V Serebrov, A Gruber, D Gailani.   

Abstract

BACKGROUND: Factor XIa is traditionally assigned a role in FIX activation during coagulation. However, recent evidence suggests this protease may have additional plasma substrates.
OBJECTIVE: To determine whether FXIa promotes thrombin generation and coagulation in plasma in the absence of FIX, and to determine whether FXI-deficiency produces an antithrombotic effect in mice independently of FIX.
METHODS: FXIa, FXIa variants and anti-FXIa antibodies were tested for their effects on plasma coagulation and thrombin generation in the absence of FIX, and for their effects on the activation of purified coagulation factors. Mice with combined FIX and FXI deficiency were compared with mice lacking either FIX or FXI in an arterial thrombosis model.
RESULTS: In FIX-deficient plasma, FXIa induced thrombin generation, and anti-FXIa antibodies prolonged clotting times. This process involved FXIa-mediated conversion of FX and FV to their active forms. Activation of FV by FXIa required the A3 domain on the FXIa heavy chain, whereas activation of FX did not. FX activation by FXIa, unlike FIX activation, was not a calcium-dependent process. Mice lacking both FIX and FXI were more resistant to ferric chloride-induced carotid artery occlusion than FXI-deficient or FIX-deficient mice.
CONCLUSION: In addition to its predominant role as an activator of FIX, FXIa may contribute to coagulation by activating FX and FV. As the latter reactions do not require calcium, they may make important contributions to in vitro clotting triggered by contact activation. The reactions may be relevant to FXIa's roles in hemostasis and in promoting thrombosis.
© 2013 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  factor IX; factor V; factor X; factor XI; factor XIa

Mesh:

Substances:

Year:  2013        PMID: 24152424      PMCID: PMC3947433          DOI: 10.1111/jth.12435

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  30 in total

Review 1.  Sequence determinants of function and evolution in serine proteases.

Authors:  M M Krem; T Rose; E Di Cera
Journal:  Trends Cardiovasc Med       Date:  2000-05       Impact factor: 6.677

2.  AN ENZYME CASCADE IN THE BLOOD CLOTTING MECHANISM, AND ITS FUNCTION AS A BIOCHEMICAL AMPLIFIER.

Authors:  R G MACFARLANE
Journal:  Nature       Date:  1964-05-02       Impact factor: 49.962

3.  High levels of coagulation factor XI as a risk factor for venous thrombosis.

Authors:  J C Meijers; W L Tekelenburg; B N Bouma; R M Bertina; F R Rosendaal
Journal:  N Engl J Med       Date:  2000-03-09       Impact factor: 91.245

4.  Factor XII promotes blood coagulation independent of factor XI in the presence of long-chain polyphosphates.

Authors:  C Puy; E I Tucker; Z C Wong; D Gailani; S A Smith; S H Choi; J H Morrissey; A Gruber; O J T McCarty
Journal:  J Thromb Haemost       Date:  2013-07       Impact factor: 5.824

5.  A coagulation factor IX-deficient mouse model for human hemophilia B.

Authors:  H F Lin; N Maeda; O Smithies; D L Straight; D W Stafford
Journal:  Blood       Date:  1997-11-15       Impact factor: 22.113

6.  Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats.

Authors:  G Z Feuerstein; A Patel; J R Toomey; P Bugelski; A J Nichols; W R Church; R Valocik; P Koster; A Baker; M N Blackburn
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-10       Impact factor: 8.311

7.  In vivo coagulation activation following infusion of highly purified factor XI concentrate.

Authors:  E M Richards; M M Makris; P Cooper; F E Preston
Journal:  Br J Haematol       Date:  1997-02       Impact factor: 6.998

8.  Activation of the coagulation cascade after infusion of a factor XI concentrate in congenitally deficient patients.

Authors:  P M Mannucci; K A Bauer; E Santagostino; E Faioni; S Barzegar; R Coppola; R D Rosenberg
Journal:  Blood       Date:  1994-08-15       Impact factor: 22.113

9.  Demonstration of exosite I-dependent interactions of thrombin with human factor V and factor Va involving the factor Va heavy chain: analysis by affinity chromatography employing a novel method for active-site-selective immobilization of serine proteinases.

Authors:  K R Dharmawardana; P E Bock
Journal:  Biochemistry       Date:  1998-09-22       Impact factor: 3.162

10.  The evolution of vertebrate blood coagulation as viewed from a comparison of puffer fish and sea squirt genomes.

Authors:  Yong Jiang; Russell F Doolittle
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-13       Impact factor: 11.205

View more
  21 in total

Review 1.  Factor XI and contact activation as targets for antithrombotic therapy.

Authors:  D Gailani; C E Bane; A Gruber
Journal:  J Thromb Haemost       Date:  2015-06-16       Impact factor: 5.824

2.  Activated factor XI increases the procoagulant activity of the extrinsic pathway by inactivating tissue factor pathway inhibitor.

Authors:  Cristina Puy; Erik I Tucker; Anton Matafonov; Qiufang Cheng; Keith D Zientek; Dave Gailani; András Gruber; Owen J T McCarty
Journal:  Blood       Date:  2015-01-13       Impact factor: 22.113

3.  Mice, men, and differences therein.

Authors:  Alisa S Wolberg
Journal:  J Thromb Haemost       Date:  2019-09       Impact factor: 5.824

Review 4.  Factor XI(a) inhibitors for thrombosis: an updated patent review (2016-present).

Authors:  Rami A Al-Horani
Journal:  Expert Opin Ther Pat       Date:  2019-12-19       Impact factor: 6.674

5.  Differential roles of factors IX and XI in murine placenta and hemostasis under conditions of low tissue factor.

Authors:  Steven P Grover; Clare M Schmedes; Alyson C Auriemma; Emily Butler; Molly L Parrish; Adam Miszta; Audrey C Cleuren; Mayken Visser; Stefan Heitmeier; Jens J Posma; Henri M Spronk; Silvio Antoniak; Alisa S Wolberg; Rafal Pawlinski; David Gailani; Nigel Mackman
Journal:  Blood Adv       Date:  2020-01-14

6.  Selective factor VIII activation by the tissue factor-factor VIIa-factor Xa complex.

Authors:  Yuichi Kamikubo; G Loredana Mendolicchio; Antonella Zampolli; Patrizia Marchese; Andrea S Rothmeier; Jennifer Nagrampa Orje; Andrew J Gale; Sriram Krishnaswamy; András Gruber; Henrik Østergaard; Lars C Petersen; Wolfram Ruf; Zaverio M Ruggeri
Journal:  Blood       Date:  2017-07-20       Impact factor: 22.113

Review 7.  Recent advances in the discovery and development of factor XI/XIa inhibitors.

Authors:  Rami A Al-Horani; Daniel K Afosah
Journal:  Med Res Rev       Date:  2018-05-04       Impact factor: 12.944

Review 8.  Plasma contact factors as therapeutic targets.

Authors:  Benjamin F Tillman; Andras Gruber; Owen J T McCarty; David Gailani
Journal:  Blood Rev       Date:  2018-04-12       Impact factor: 8.250

Review 9.  The hemostatic role of factor XI.

Authors:  Cristina Puy; Rachel A Rigg; Owen J T McCarty
Journal:  Thromb Res       Date:  2016-05       Impact factor: 3.944

10.  Abnormal plasma clot formation and fibrinolysis reveal bleeding tendency in patients with partial factor XI deficiency.

Authors:  Gillian N Gidley; Lori A Holle; John Burthem; Paula H B Bolton-Maggs; Feng-Chang Lin; Alisa S Wolberg
Journal:  Blood Adv       Date:  2018-05-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.